IL15 can reverse the unresponsiveness of Wilms' tumor antigen-specific CTL in patients with prostate cancer.

@article{King2009IL15CR,
  title={IL15 can reverse the unresponsiveness of Wilms' tumor antigen-specific CTL in patients with prostate cancer.},
  author={Judy W King and Sharyn Thomas and F. Corsi and Liquan Gao and Roberto Dina and Roopinder Gillmore and Katharine Pigott and Amir V. Kaisary and Hans J Stauss and Jonathan A. Waxman},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2009},
  volume={15 4},
  pages={1145-54}
}
PURPOSE The Wilms' tumor antigen 1 (WT1) is overexpressed in several leukemias and solid tumors, but there is currently limited information regarding its role in prostate cancer. This study aimed to investigate WT1 expression in prostate cancer, and to determine the number and function of WT1-specific T cells in the peripheral blood of patients. EXPERIMENTAL DESIGN Immunohistochemistry was used to assess WT1 expression in cancer tissues. Human leukocyte antigen A2 (HLA-A2) tetramers served to… CONTINUE READING

6 Figures & Tables

Connections & Topics

Mentioned Connections BETA
Human leukocyte antigen A2 ( HLA - A2 ) tetramers served to detect WT1-specific T cells , and peptide - specific stimulation was used to assess T - cell function in vitro .
All Topics